Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
Vittorio PavoniLara GianeselloAndrew HortonPublished in: Journal of thrombosis and thrombolysis (2021)
Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.
Keyphrases
- venous thromboembolism
- coronavirus disease
- sars cov
- poor prognosis
- respiratory syndrome coronavirus
- direct oral anticoagulants
- long non coding rna
- systemic lupus erythematosus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systematic review
- peritoneal dialysis
- pulmonary embolism
- risk factors
- patient reported outcomes
- atrial fibrillation
- patient reported